| Exploiting the message from cancer: The diagnostic value of extracellular vesicles for clinical applications N Kosaka, A Kogure, T Yamamoto, F Urabe, W Usuba, M Prieto-Vila, ... Experimental & molecular medicine 51 (3), 1-9, 2019 | 121 | 2019 |
| Latest advances in extracellular vesicles: from bench to bedside T Yamamoto, N Kosaka, T Ochiya Science and Technology of Advanced Materials 20 (1), 746-757, 2019 | 93 | 2019 |
| Delivery of miR-424-5p via Extracellular vesicles promotes the apoptosis of MDA-MB-231 TNBC cells in the tumor microenvironment Y Zhou, Y Yamamoto, F Takeshita, T Yamamoto, Z Xiao, T Ochiya International journal of molecular sciences 22 (2), 844, 2021 | 57 | 2021 |
| miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4, and CHORDC1 F Urabe, N Kosaka, Y Sawa, Y Yamamoto, K Ito, T Yamamoto, T Kimura, ... Science advances 6 (18), eaay3051, 2020 | 56 | 2020 |
| Long non‐coding NR2F1‐AS1 is associated with tumor recurrence in estrogen receptor‐positive breast cancers A Sanchez Calle, T Yamamoto, Y Kawamura, A Hironaka‐Mitsuhashi, ... Molecular oncology 14 (9), 2271-2287, 2020 | 22 | 2020 |
| Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma K Yoshida, A Yokoi, T Yamamoto, Y Hayashi, J Nakayama, T Yokoi, ... Clinical Cancer Research 28 (10), 2147-2159, 2022 | 19 | 2022 |
| Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer K Yamaguchi, T Yamamoto, J Chikuda, T Shirota, Y Yamamoto Biomolecules 12 (2), 284, 2022 | 16 | 2022 |
| Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ M Tokura, J Nakayama, M Prieto-Vila, S Shiino, M Yoshida, T Yamamoto, ... Cancer Research 82 (18), 3236-3248, 2022 | 14 | 2022 |
| A challenge to aging society by microRNA in extracellular vesicles: MicroRNA in extracellular vesicles as promising biomarkers and novel therapeutic targets in multiple myeloma T Yamamoto, N Kosaka, Y Hattori, T Ochiya Journal of Clinical Medicine 7 (3), 55, 2018 | 14 | 2018 |
| SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma T Yamamoto, J Nakayama, Y Yamamoto, M Kuroda, Y Hattori, T Ochiya Blood Advances 6 (8), 2480-2495, 2022 | 13 | 2022 |
| Comprehensive serum and tissue microRNA profiling in dedifferentiated liposarcoma I Kohama, N Asano, J Matsuzaki, Y Yamamoto, T Yamamoto, ... Oncology Letters 22 (2), 1-8, 2021 | 13 | 2021 |
| Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach K Yoshida, A Yokoi, M Kitagawa, M Sugiyama, T Yamamoto, J Nakayama, ... Oncology Reports 49 (5), 1-9, 2023 | 6 | 2023 |
| Extracellular vesicle-mediated immunoregulation in cancer T Yamamoto, Y Yamamoto, T Ochiya International Journal of Hematology 117 (5), 640-646, 2023 | 6 | 2023 |
| Osteoblast‐derived extracellular vesicles exert osteoblastic and tumor‐suppressive functions via SERPINA3 and LCN2 in prostate cancer K Ito, T Yamamoto, Y Hayashi, S Sato, J Nakayama, F Urabe, T Shimasaki, ... Molecular Oncology 17 (10), 2147-2167, 2023 | 3 | 2023 |
| Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress I Shimomura, N Watanabe, T Yamamoto, M Kumazaki, Y Tada, K Tatsumi, ... JCI insight 6 (7), 2021 | 3 | 2021 |
| Understanding the Role of Extracellular Vesicles in Lenalidomide-Resistance Multiple Myeloma T Yamamoto, N Kosaka, O Takahiro, Y Hattori Blood 132, 1887, 2018 | 3 | 2018 |
| Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells Y Hattori, T Futo, R Uozaki, D Ichikawa, T Yamaguchi, T Yamamoto, ... International journal of hematology 115 (4), 605-608, 2022 | 2 | 2022 |
| Aberrant regulation of serine metabolism drives extracellular vesicle release and cancer progression T Yamamoto, J Nakayama, F Urabe, K Ito, N Nishida-Aoki, M Kitagawa, ... Cell Reports 43 (8), 114517, 2024 | 1 | 2024 |
| Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma S Kashiwazaki, S Kamiko, R Uozaki, T Yamamoto, D Ichikawa, Y Hattori, ... Blood 132, 1946, 2018 | 1 | 2018 |
| 10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan K Suzuki, T Yamamoto, M Ikeda, T Takei, N Tsukada, T Ishida, A Ueda, ... Blood 128 (22), 5620, 2016 | 1 | 2016 |
Yusuke YamamotoNational Cancer Center Research Institute在 ncc.go.jp 的电子邮件经过验证
